TALIDEX |
K-17 |
THALIDOMIDE |
NSC-66847 |
NSC-527179 |
THALOMID |
THALIDOMIDE |
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE |
Α-(N-PHTHALIMIDO)GLUTARIMIDE |
(±)-THALIDOMIDE |
Α-PHTHALIMIDOGLUTARIMIDE |
(+-)-THALIDOMIDE |
TALIDOMIDA |
Α-N-PHTHALYLGLUTARAMIDE |
N-PHTHALYL-GLUTAMINSAEURE-IMID |
N-PHTHALYLGLUTAMIC ACID IMIDE |
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE |
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE |
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE |
3-PHTHALIMIDOGLUTARIMIDE |
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE |
THALIDOMIDUM |
N-PHTHALOYLGLUTAMIMIDE |
ALPHA-N-PHTHALYLGLUTARAMIDE |
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE |
drugbank:01041 |
chembl:CHEMBL468 |
rxcui:10432 |
pubchem.compound:5426 |
chemidplus:50-35-1 |
Drug Categories | growth inhibitors |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
Year of Approval | approved before 1982 |
Drug Class | leprostatic agents |
Drug Class | immunosuppressive agents |
Drug Categories | cardiotoxic antineoplastic agents |
Drug Categories | cytochrome p-450 cyp2c19 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a inducers |
Drug Categories | cytochrome p-450 cyp3a5 inducers |
Drug Categories | cytochrome p-450 cyp3a5 inducers (strength unknown) |
Drug Categories | cytochrome p-450 enzyme inducers |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | decreased immunologically active molecule activity |
Drug Categories | drugs causing inadvertant photosensitivity |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | immunomodulatory agents |
Drug Categories | photosensitizing agents |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Binding |
inhibitor (inhibitory) |
Mechanism of Interaction | CRL4(CRBN) E3 ubiquitin ligase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | CRL4(CRBN) E3 ubiquitin ligase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | CRL4(CRBN) E3 ubiquitin ligase inhibitor |
antagonist (inhibitory) |
Trial Name | Thalomid |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | Thalomid |
Novel drug target | Established target |
50-35-1 | CAS Number |
Contergan | Drug Brand |
Distaval | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Class | immunosuppressive agents |
Drug Class | leprostatic agents |
Year of Approval | approved before 1982 |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
C870 | NCI drug code |
D0U7GK | TTD Drug ID |